Bellevue Group’s Viridian Therapeutics VRDN Stock Holding History

Bellevue Group’s Portfolio VRDN Stock Details VRDN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$124M	Buy	6,731,909 +5,765	+0.1%	+$92.9K	2.6%	10
2026 Q1	$132M	Buy	6,726,144 +2,367,617	+54%	+$70.3M	3.13%	9
2025 Q4	$136M	Buy	+4,358,527	New	+$120M	2.57%	13
2024 Q2	–	Sell	-19,100	Closed	-$334K	–	177
2024 Q1	$334K	Sell	19,100 -10,900	-36%	-$211K	0.01%	144
2023 Q4	$653K	Sell	30,000 -33,770	-53%	-$533K	0.01%	129
2023 Q3	$978K	Buy	63,770 +19,370	+44%	+$370K	0.02%	129
2023 Q2	$1.06M	Sell	44,400 -1,700	-4%	-$43.6K	0.02%	129
2023 Q1	$1.17M	Hold	46,100	–	–	0.02%	125
2022 Q4	$1.35M	Hold	46,100	–	–	0.02%	133
2022 Q3	$946K	Sell	46,100 -2,900	-6%	-$52.1K	0.01%	138
2022 Q2	$567K	Buy	+49,000	New	+$659K	0.01%	147

Other funds holding VRDN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Bellevue Group's VRDN Position: Q2 2026 in Review

Bellevue Group increased its Viridian Therapeutics (VRDN) stake by 0.09% in Q2 2026, buying an estimated $92.9K and bringing the position to 6,731,909 shares worth $124M. The position accounts for 2.6% of the portfolio, ranked #10.

Bellevue Group first reported a position in VRDN in Q2 2022 and has held it in 11 quarters since. The position peaked at $136M in Q4 2025. 214 funds tracked by Wall St. Rank hold VRDN as of Q2 2026.

Bellevue Group held 6,731,909 shares of Viridian Therapeutics worth $124M as of Q2 2026.
Bellevue Group bought 5,765 Viridian Therapeutics shares in Q2 2026, an estimated $92.9K.
Viridian Therapeutics made up 2.6% of Bellevue Group's portfolio in Q2 2026, its #10 holding.
Bellevue Group first reported a position in Viridian Therapeutics in Q2 2022 and has held it in 11 quarters since.
Bellevue Group's Viridian Therapeutics position peaked at $136M in Q4 2025.
214 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2026.

Based on Bellevue Group's 13F filing for Q2 2026, filed 14 Aug 2026.